BACKGROUND In hepatocellular carcinoma(HCC),detection and treatment prior to growth beyond 2 cm are relevant as a larger tumor size is more frequently associated with microvascular invasion and/or satellites.AIM To ex...BACKGROUND In hepatocellular carcinoma(HCC),detection and treatment prior to growth beyond 2 cm are relevant as a larger tumor size is more frequently associated with microvascular invasion and/or satellites.AIM To examine the impact of the tumor marker alpha-fetoprotein(AFP)or PIVKA-II in detecting very small HCC nodules(≤2 cm in maximum diameter,Barcelona stage 0)in the large number of very small HCC.The difference in the behavior of these tumor markers in HCC development was also examined.METHODS A total of 933 patients with single-nodule HCC were examined.They were subdivided into 394 patients with HCC nodules≤2 cm in maximum diameter and 539 patients whose nodules were>2 cm.The rates of patients whose AFP and PIVKA-II showed normal values were examined.RESULTS The positive ratio of the marker PIVKA-II was significantly different(P<0.0001)between patients with nodules≤2 cm in diameter and those with nodules>2 cm,but there was no significant difference in AFP(P=0.4254).In the patients whose tumor was≤2 cm,50.5%showed normal levels in AFP and 68.8%showed normal levels in PIVKA-II.In 36.4%of those patients,both AFP and PIVKA-II showed normal levels.The PIVKA-II-positive ratio was markedly increased with an increase in the tumor size.In contrast,the positivity in AFP was increased gradually and slowly.CONCLUSION In the surveillance of very small HCC nodules(≤2 cm in diameter,Barcelona clinical stage 0)the tumor markers AFP and PIVKA-II are not so useful.展开更多
目的探究异常凝血酶原(PIVKA-Ⅱ)与甲胎蛋白(AFP)对原发性肝癌(HCC)的诊断价值。方法将2012年1月1日至2016年12月31日乐山市人民医院肝胆外科就诊的128例患者纳入研究,其中原发性肝癌85例,肝硬化43例。测定术前、术后血清及组织中PIVKA...目的探究异常凝血酶原(PIVKA-Ⅱ)与甲胎蛋白(AFP)对原发性肝癌(HCC)的诊断价值。方法将2012年1月1日至2016年12月31日乐山市人民医院肝胆外科就诊的128例患者纳入研究,其中原发性肝癌85例,肝硬化43例。测定术前、术后血清及组织中PIVKA-Ⅱ及AFP的浓度。运用受试者工作特性曲线(ROC)分析PIVKA-II及AFP的检测效能,确定其检测HCC的临界值及敏感度和特异度。对HCC患者进行变量分析,以确定肿瘤组织微血管侵袭性(MVI)的潜在预测因子。对术中采集的肿瘤及各相邻非瘤肝块进行免疫组化半定量分析并予以评分。结果 HCC组患者的PIVKA-Ⅱ中位浓度为136 m AU/m L,明显高于肝硬化组的26 m AU/m L,差异有显著统计学意义(P<0.01);而两组患者的AFP中位浓度比较差异无统计学意义(P>0.05)。血清PIVKA-Ⅱ诊断HCC的曲线下面积为[0.544(95%CI:0.444~0.645)],优于AFP诊断HCC的能力[0.453(95%CI:0.350~0.555)]。对于HCC的诊断,PIVKA-Ⅱ检测早期HCC的最佳临界值(Cut-off)为42 m AU/m L,此时检测HCC敏感度为77%,特异度为82%;AFP检测早期HCC的(Cut-off)值为5.8 ng/m L,此时其检测HCC的灵敏度为61%,特异度为50%。PIVKA-Ⅱ>90 m AU/m L(HR 3.5;95%CI,1.08~11.8;P=0.043)和中度/低分化肿瘤(HR 3.4;95%CI,1.04~11.05;P=0.037)是MVI独立的预测因素。结论 PIVKA-Ⅱ比AFP对早期原发性肝癌有更高的敏感性和特异性。此外,将PIVKA-Ⅱ血清水平和组织表达作为MVI的术前生物标志物使用,可以提高早期原发性肝癌的诊断效率,对肿瘤预后评估有较高的临床应用价值。展开更多
目的:探讨异常凝血酶原(protein induced by vitamin K absence or antagonist-Ⅱ,PIVKA-Ⅱ)与高尔基体蛋白(Golgi glycoprotein,GP73)联合检测对诊断血清甲胎蛋白(alpha-fetoprotein,AFP)低浓度的原发性肝癌(primary hepatic carcinoma...目的:探讨异常凝血酶原(protein induced by vitamin K absence or antagonist-Ⅱ,PIVKA-Ⅱ)与高尔基体蛋白(Golgi glycoprotein,GP73)联合检测对诊断血清甲胎蛋白(alpha-fetoprotein,AFP)低浓度的原发性肝癌(primary hepatic carcinoma,PHC)的临床价值。方法:选取本院2015年3月-2016年12月AFP低浓度PHC72例,其他肝病68例,同期体检正常对照组110例,分别检测PIVKA-Ⅱ(ELISA)和GP73(ELISA)、AFP(化学发光法)的血清浓度水平。结果:PIVKA-Ⅱ与GP73联合检测在AFP低浓度PHC的系列试验特异度高达100%,联合试验敏感度达90.2%。结论:单独检测PIVKA-Ⅱ和GP73对AFP低浓度肝癌具有较高的诊断价值,PIVKA-Ⅱ与GP73联合检测可提高AFP低浓度肝癌诊断。展开更多
文摘BACKGROUND In hepatocellular carcinoma(HCC),detection and treatment prior to growth beyond 2 cm are relevant as a larger tumor size is more frequently associated with microvascular invasion and/or satellites.AIM To examine the impact of the tumor marker alpha-fetoprotein(AFP)or PIVKA-II in detecting very small HCC nodules(≤2 cm in maximum diameter,Barcelona stage 0)in the large number of very small HCC.The difference in the behavior of these tumor markers in HCC development was also examined.METHODS A total of 933 patients with single-nodule HCC were examined.They were subdivided into 394 patients with HCC nodules≤2 cm in maximum diameter and 539 patients whose nodules were>2 cm.The rates of patients whose AFP and PIVKA-II showed normal values were examined.RESULTS The positive ratio of the marker PIVKA-II was significantly different(P<0.0001)between patients with nodules≤2 cm in diameter and those with nodules>2 cm,but there was no significant difference in AFP(P=0.4254).In the patients whose tumor was≤2 cm,50.5%showed normal levels in AFP and 68.8%showed normal levels in PIVKA-II.In 36.4%of those patients,both AFP and PIVKA-II showed normal levels.The PIVKA-II-positive ratio was markedly increased with an increase in the tumor size.In contrast,the positivity in AFP was increased gradually and slowly.CONCLUSION In the surveillance of very small HCC nodules(≤2 cm in diameter,Barcelona clinical stage 0)the tumor markers AFP and PIVKA-II are not so useful.
文摘目的探究异常凝血酶原(PIVKA-Ⅱ)与甲胎蛋白(AFP)对原发性肝癌(HCC)的诊断价值。方法将2012年1月1日至2016年12月31日乐山市人民医院肝胆外科就诊的128例患者纳入研究,其中原发性肝癌85例,肝硬化43例。测定术前、术后血清及组织中PIVKA-Ⅱ及AFP的浓度。运用受试者工作特性曲线(ROC)分析PIVKA-II及AFP的检测效能,确定其检测HCC的临界值及敏感度和特异度。对HCC患者进行变量分析,以确定肿瘤组织微血管侵袭性(MVI)的潜在预测因子。对术中采集的肿瘤及各相邻非瘤肝块进行免疫组化半定量分析并予以评分。结果 HCC组患者的PIVKA-Ⅱ中位浓度为136 m AU/m L,明显高于肝硬化组的26 m AU/m L,差异有显著统计学意义(P<0.01);而两组患者的AFP中位浓度比较差异无统计学意义(P>0.05)。血清PIVKA-Ⅱ诊断HCC的曲线下面积为[0.544(95%CI:0.444~0.645)],优于AFP诊断HCC的能力[0.453(95%CI:0.350~0.555)]。对于HCC的诊断,PIVKA-Ⅱ检测早期HCC的最佳临界值(Cut-off)为42 m AU/m L,此时检测HCC敏感度为77%,特异度为82%;AFP检测早期HCC的(Cut-off)值为5.8 ng/m L,此时其检测HCC的灵敏度为61%,特异度为50%。PIVKA-Ⅱ>90 m AU/m L(HR 3.5;95%CI,1.08~11.8;P=0.043)和中度/低分化肿瘤(HR 3.4;95%CI,1.04~11.05;P=0.037)是MVI独立的预测因素。结论 PIVKA-Ⅱ比AFP对早期原发性肝癌有更高的敏感性和特异性。此外,将PIVKA-Ⅱ血清水平和组织表达作为MVI的术前生物标志物使用,可以提高早期原发性肝癌的诊断效率,对肿瘤预后评估有较高的临床应用价值。
文摘目的:探讨异常凝血酶原(protein induced by vitamin K absence or antagonist-Ⅱ,PIVKA-Ⅱ)与高尔基体蛋白(Golgi glycoprotein,GP73)联合检测对诊断血清甲胎蛋白(alpha-fetoprotein,AFP)低浓度的原发性肝癌(primary hepatic carcinoma,PHC)的临床价值。方法:选取本院2015年3月-2016年12月AFP低浓度PHC72例,其他肝病68例,同期体检正常对照组110例,分别检测PIVKA-Ⅱ(ELISA)和GP73(ELISA)、AFP(化学发光法)的血清浓度水平。结果:PIVKA-Ⅱ与GP73联合检测在AFP低浓度PHC的系列试验特异度高达100%,联合试验敏感度达90.2%。结论:单独检测PIVKA-Ⅱ和GP73对AFP低浓度肝癌具有较高的诊断价值,PIVKA-Ⅱ与GP73联合检测可提高AFP低浓度肝癌诊断。
